Antistaminici H1 - H2 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-004068-24-IT
(EUCTR)
21/05/202102/08/2021Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis BronchiectasisA Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE) - MAHALE Non-cystic fibrosis bronchiectasis (NCFB)
MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: NA
Product Name: benralizumab
Product Code: [MEDI-563]
INN or Proposed INN: benralizumab
Other descriptive name: benralizumab
Product Name: Atropina
Product Code: [NA]
Product Name: Antistaminici H1 - H2
Product Code: [na]
Product Name: C01CA04 - Dopamina
Product Code: [na]
Product Name: Adrenalina
Product Code: [NA]
Product Name: Salbutamolo
Product Code: [NA]
Product Name: H02 - Corticosteroidi Sistemici
Product Code: [NA]
ASTRAZENECA ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
420Phase 3United States;Philippines;Spain;Russian Federation;United Kingdom;Italy;India;Vietnam;Canada;Argentina;Poland;Australia;Denmark;Germany;China;Korea, Republic of